Determinants of Resistance to Checkpoint Inhibitors

被引：34

作者：

Tran, Linda ^{[1
,2
]}

Theodorescu, Dan ^{[1
,2
,3
,4
]}

机构：

[1] Cedars Sinai Med Ctr, Dept Surg Urol, Los Angeles, CA 90048 USA

[2] Cedars Sinai Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

[3] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA

[4] Cedars Sinai Hlth Syst, 8700 Beverly Blvd,OCC Mezz C2002, Los Angeles, CA 90048 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 05期

关键词：

cancer; immunotherapy; combination therapy; immune checkpoints; immune checkpoint inhibitors; functional genomics; next generation sequencing; prognostic markers; predictive markers; CELL LUNG-CANCER; FOCAL-ADHESION KINASE; TUMOR-INFILTRATING LYMPHOCYTES; NIVOLUMAB PLUS IPILIMUMAB; LONG-TERM SURVIVAL; CAR T-CELLS; ACQUIRED-RESISTANCE; CTLA-4; BLOCKADE; PD-1; ANTITUMOR IMMUNITY;

D O I：

10.3390/ijms21051594

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The development of immune checkpoint inhibitors (ICIs) has drastically altered the landscape of cancer treatment. Since approval of the first ICI for the treatment of advanced melanoma in 2011, several therapeutic agents have been Food and Drug Administration (FDA)-approved for multiple cancers, and hundreds of clinical trials are currently ongoing. These antibodies disrupt T-cell inhibitory pathways established by tumor cells and thus re-activate the host's antitumor immune response. While successful in many cancers, several types remain relatively refractory to treatment or patients develop early recurrence. Hence, there is a great need to further elucidate mechanisms of resistant disease and determine novel, effective, and tolerable combination therapies to enhance efficacy of ICIs.

引用

页数：21

共 197 条

[1] Systematic review of case reports on the abscopal effect [J].

Abuodeh, Yazan ;

Venkat, Puja ;

Kim, Sungjune .

CURRENT PROBLEMS IN CANCER, 2016, 40 (01) :25-37

[2] Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study [J].

Adams, S. ;

Schmid, P. ;

Rugo, H. S. ;

Winer, E. P. ;

Loirat, D. ;

Awada, A. ;

Cescon, D. W. ;

Iwata, H. ;

Campone, M. ;

Nanda, R. ;

Hui, R. ;

Curigliano, G. ;

Toppmeyer, D. ;

O'Shaughnessy, J. ;

Loi, S. ;

Paluch-Shimon, S. ;

Tan, A. R. ;

Card, D. ;

Zhao, J. ;

Karantza, V. ;

Cortes, J. .

ANNALS OF ONCOLOGY, 2019, 30 (03) :397-404

[3] Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis [J].

Addeo, Alfredo ;

Banna, Giuseppe Luigi ;

Metro, Giulio ;

Di Maio, Massimo .

FRONTIERS IN ONCOLOGY, 2019, 9

[4] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[5] Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells [J].

Alizadeh, Darya ;

Larmonier, Nicolas .

CANCER RESEARCH, 2014, 74 (10) :2663-2668

[6] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Zhang, Theresa ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Zahnow, Cynthia A. ;

Baylin, Stephen B. ;

Scharpf, Robert B. ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2017, 7 (03) :264-276

[7]

Anassi Enock, 2011, P T, V36, P197

[8] Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment [J].

Anderson, Erik S. ;

Postow, Michael A. ;

Wolchok, Jedd D. ;

Young, Robert J. ;

Ballangrud, Ase ;

Chan, Timothy A. ;

Yamada, Yoshiya ;

Beal, Kathryn .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

[9] Human T helper type 1 dichotomy: origin, phenotype and biological activities [J].

Annunziato, Francesco ;

Cosmi, Lorenzo ;

Liotta, Francesco ;

Maggi, Enrico ;

Romagnani, Sergio .

IMMUNOLOGY, 2015, 144 (03) :343-351

[10] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study [J].

Antonarakis, Emmanuel S. ;

Piulats, Josep M. ;

Gross-Goupil, Marine ;

Goh, Jeffrey ;

Ojamaa, Kristiina ;

Hoimes, Christopher J. ;

Vaishampayan, Ulka ;

Berger, Ranaan ;

Sezer, Ahmet ;

Alanko, Tuomo ;

de Wit, Ronald ;

Li, Chunde ;

Omlin, Aurelius ;

Procopio, Giuseppe ;

Fukasawa, Satoshi ;

Tabata, Ken-ichi ;

Park, Se Hoon ;

Feyerabend, Susan ;

Drake, Charles G. ;

Wu, Haiyan ;

Qiu, Ping ;

Kim, Jeri ;

Poehlein, Christian ;

de Bono, Johann Sebastian .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

← 1 2 3 4 5 6 7 8 9 10 →